Targets for Anti-T. cruzi Drugs in the Post-Genomic Era

Author(s): Alicia Merlino, Mercedes Gonzalez, Hugo Cerecetto

Journal Name: Current Enzyme Inhibition

Volume 6 , Issue 4 , 2010

Become EABM
Become Reviewer


The information of the complete genome sequences of Trypanosoma cruzi revealed that its genome contains nearly to 10,000 protein-coding genes. This vast amount of new information allows the identification of therapeutic targets in an accurate and undoubtedly forms. The current post-genomic period is a special moment in the anti-T. cruzi drug discovery and development ushering this moment as the anti-Chagas drug discovery era. In this review we describe, from a medicinal chemistry point of view, several identified potential biological targets for drugs development. We discuss the validity and druggability as anti-Chagas objectives of prenyl converting and transferring enzymes, cAMP-specific phosphodiesterases, polyamine and trypanothione synthetic pathways, triosephosphate isomerase, α-hydroxyacid dehydrogenases and trans-sialidase.

Keywords: Chagas' disease, enzymatic inhibitors, drugs development, Trypanosoma cruzi, ergosterol biosynthetic pathway, trypanothione reductase, farnesyltransferase inhibitors, cAMP-specific phosphodiesterases, Dipyridamole, sulfinyl radicals, glutathionylated products

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [195 - 210]
Pages: 16
DOI: 10.2174/157340810794578533
Price: $65

Article Metrics

PDF: 12